On October 8, Nexalin Technology announced it had regained compliance with Nasdaq's minimum bid price requirement after the Nasdaq Hearings Panel granted its request for continued listing. The following day, Veea reported achieving full compliance with Nasdaq requirements, triggering a surge in its share price. In contrast, Nasdaq announced its intention to suspend trading in Pomdoctor securities due to non-compliance with listing standards.
Nasdaq notified Pomdoctor of its intent to suspend trading in its securities starting October 15, 2026, following the company's failure to meet continued listing standards.
Read the full storyVeea has resolved its governance deficiencies and met all exchange requirements, removing the immediate risk of delisting and triggering a relief rally in its shares.
The medical technology firm met Nasdaq's minimum bid price requirements following a panel decision to grant the company's request for continued listing.
